Drug intelligence / Profile preview

valinomycin

Development stage
Preclinical
Lead developer
Streptomyces fulvissimus (natural producer)
Modality
Small Molecules, Peptides
Administration
Not Typically Administered Clinically; Used Experimentally In Vitro.
01

Overview

Valinomycin is a naturally occurring cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related Streptomyces species[1][4][6]. It consists of three units each of L-valine, D-valine, D-alpha-hydroxyisovaleric acid, and L-lactic acid linked alternately to form a 36-membered macrocyclic ring[1][6]. Valinomycin acts as a highly selective potassium ion transporter across lipid membranes, facilitating the movement of K⁺ ions down their electrochemical gradient while excluding sodium ions due to its structural selectivity[4][7]. This disrupts cellular ionic balance and can induce cell death through membrane depolarization. Its primary use is as a biochemical tool in research; it has also demonstrated potent antiviral activity in vitro (e.g., against SARS-CoV)[3], but its high toxicity limits therapeutic application. Valinomycin is extremely toxic to mammals as well as bacteria due to its non-selective disruption of cellular ionic gradients[5][7].

Other names
potassium ionophore Ivalinomicinvalino
02

Targets

KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)

Beyond the preview

Go deeper on valinomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on valinomycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call